Switching the chemical immune-suppressive regimen from cyclosporine A/FK506 to mammalian target of rapamycin (mTOR) inhibitors such as rapamycin/sirolimus/everolimus often leads to KS regression [27,28]. This evidence concerns the gene MTOR and Kaposi's sarcoma.